CELLECTIS S.A.

Products

Category

Product

Brand

Description

Current Research and Development Status of Chimeric Antigen Receptor (CAR) T-Cell Therapy Market (BIO162C)

UCART22 CD22 (Phase 1 Dose Escalation)		A potential allogeneic CAR T-cell product that targets CD22 is called UCART22. Patients with relapsed or refractory B-cell acute lymphoblastic leukemia (r/r B-ALL) are being assessed for UCART22.
UCART20x22 Dual Target CD20, CD22 (Phase 1 Dose Escalation)		The first allogeneic dual CAR T-cell product candidate from Cellectis, UCART20x22, targets both CD20 and CD22 and is being developed for patients with refractory or relapsed B-cell non-Hodgkin lymphoma (r/r B-NHL). Dual targeting is intended to improve the destruction of tumor cells and stop immune escape brought on by single antigen targeting.
Cemacabtagene Ansegedleucel (ALLO-501A) CD19 (Phase 2 Pivotal)		The anti-CD19 allogeneic CAR T (AlloCAR T) product CEMACABTAGENE ANSEGEDLEUCEL (formerly known as ALLO-501A) is being developed as a first-line treatment (1L) for patients with newly diagnosed and treated large B-cell lymphoma (LBCL) who are likely to relapse after 1L of chemoimmunotherapy and require additional therapy.

This information is available for BCC Research members only.

Already a Member? Sign In Become a Member

Stay Informed

Join our mailing list for the latest report releases and upcoming event notifications.

Headquartered in Boston, Mass., for over 50 years, BCC Research takes pride in being your trusted custom research and data analysts. Our mission is to provide businesses with reputable data and market research reports, so that they gain new perspectives into their field and better understand their target audience. We enable companies to access reliable information, accurate forecasts, and actionable insights, so that they may become leaders in their industry.

AI Sentiment